CLINICAL_TRIALS
trial_result
· 2021-09-02
Clinical Trial Update: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease [Phase 3]
Summary
Phase 3 trial update for aducanumab (BIIB037) in early Alzheimer's disease; study terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-09-02